Professor Tim Eisen
Personal home page:
PubMed journal articles - click here
Professor Tim Eisen is pleased to consider applications from prospective PhD students.
I am a clinical trialist interested in developing new treatments for advanced disease, identifying and managing those at risk of disease. My current clinical interests are the research and management of kidney cancer. In kidney cancer I have been particularly involved in the development of tyrosine kinase inhibitors as therapeutic agents.
I am currently on 5 years partial leave of absence to work in AstraZeneca, where I am currently responsible for oncology trials from first in man to Phase II.
Symplectic Elements feed provided by Research Information, University of Cambridge
*Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM: TARGET Study Group. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007 Jan 11;356(2): 125-34 *Eisen T, Ahmad T, Flaherty KT, Gore M, Kaye S, Marais R, Gibbens I, Hackett S, James M, Schuchter LM, Nathanson KL, Xia C, Simantov R, Schwartz B, Poulin-Costello M, O'Dwyer PJ, Ratain MJ. Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. Br J Cancer. 2006 Sep 4;95(5):581-6. Amos CI, Wu X, Broderick P, Gorlov IP, Gu J, Eisen T, Dong Q, Zhang Q, Gu X, Vijayakrishnan J, Sullivan K, Matakidou A, Wang Y, Mills G, Doheny K, Tsai YY, Chen WV, Shete S, Spitz MR, Houlston RS. Nat Genet. 2008 May;40(5):616:22